FDA CRL - Hugel, Inc

Hugel, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its Biologics License Application (BLA 761225) for letibotulinumtoxinA injection. Submitted under section 351(a) of the Public Health Service Act, the application cannot be approved in its current state. The main issue arose from a recent inspection of Hugel, Inc.'s manufacturing and testing facility, where FDA investigators identified deficiencies requiring satisfactory resolution. The FDA also deferred comments on the proposed prescribing information, carton, and container labeling until the primary issues are resolved. While the proprietary name, Letybo, was deemed acceptable, it must be resubmitted alongside other responses. Hugel, Inc. is mandated to provide a comprehensive safety update, including detailed changes in the safety profile, new and combined clinical trial data, updated exposure information, a summary of worldwide experience, and English translations of foreign labeling. To secure approval, Hugel, Inc. must fully address all deficiencies and resubmit the application within one year. The company may not market the drug product until formal written approval is received.